Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in San Giovanni Rotondo – page 3

159 clinical trials in San Giovanni Rotondo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
San Giovanni Rotondo at a glance
159
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

159 trials in San Giovanni Rotondo

Open in trial search

Colorectal cancer metastatic

Recruiting

Comparing irinotecan plus cetuximab with trifluridine and tipiracil plus bevacizumab for patients with metastatic colorectal cancer as third line treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gruppo Oncologico Dell'Italia Meridionale

Cytomegalovirus infection+1

Recruiting

A Study of Maribavir for Cytomegalovirus Infection in Stem Cell Transplant Patients Who Cannot Take or Did Not Tolerate Standard Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Maribavir
  • Sponsor:Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare

Rectal cancer

Recruiting

Study of XELOX chemotherapy with or without dostarlimab after chemoradiation in patients with locally advanced rectal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Generalised tonic-clonic seizure+1

Recruiting

Study of PRAX-628 to evaluate safety and effectiveness in adults with epilepsy who have focal seizures or generalized tonic-clonic seizures

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:PRAX-628
  • Sponsor:Praxis Precision Medicines Inc.

Colitis ulcerative

Recruiting

Study of risankizumab safety and effectiveness in children and teenagers aged 2-17 years with moderate to severe ulcerative colitis

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma

Recruiting

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Colorectal cancer

Recruiting

Study comparing cetuximab with chemotherapy versus bevacizumab with chemotherapy in patients with advanced colorectal cancer who have wild-type RAS and right-sided tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione GONO G.I.

Acute myeloid leukaemia

Recruiting

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Janssen Cilag International

Primary biliary cholangitis

Recruiting

Study of Seladelpar Treatment in Patients with Primary Biliary Cholangitis and Compensated Cirrhosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Seladelpar
  • Sponsor:Gilead Sciences Inc.

Colorectal cancer metastatic

Recruiting

Study on Cetuximab and Drug Combination for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gruppo Oncologico Dell'Italia Meridionale

Colorectal cancer metastatic

Recruiting

Study on Regorafenib for Patients with Advanced RAS-Mutant Colorectal Cancer Using Regorafenib and Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Oesophageal cancer metastatic+3

Recruiting

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Daiichi Sankyo Inc.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in San Giovanni Rotondo

What the registry says about research in the country

01 Gastrointestinal Oncology

Clinical research focusing on metastatic colorectal cancer and gastroesophageal cancers, evaluating novel combination therapies and targeted treatments.

  • Advanced colorectal cancer treatments
  • HER2-positive gastric cancer therapies
  • Targeted molecular therapies
02 Inflammatory Bowel Disease

Studies examining innovative treatments for Crohn's Disease and Ulcerative Colitis, testing new therapeutic combinations and treatment strategies.

  • Novel biological therapies
  • Combination treatment approaches
  • Disease remission strategies
03 Hematologic Malignancies

Research initiatives in acute myeloid leukemia, multiple myeloma, and other blood cancers, exploring innovative therapeutic approaches.

  • Targeted leukemia treatments
  • Novel drug combinations
  • Immunotherapy approaches
04 Breast and Urological Cancers

Investigations into early breast cancer treatments and therapies for prostate cancer, with focus on hormone-responsive diseases.

  • Endocrine therapy optimization
  • Advanced prostate cancer treatments
  • Targeted therapeutic approaches
Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.